DDInter904 DDInter178
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Idarubicin {u} (Compound) treats {v} (Disease) breast cancer
Idarubicin {u} (Compound) binds {v} (Gene) CYP2C9
Idarubicin {u} (Compound) upregulates {v} (Gene) MEGF8
Idarubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Idarubicin {u} (Compound) downregulates {v} (Gene) CBR3
Idarubicin {u} (Compound) causes {v} (Side Effect) Haemorrhage
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Idarubicin (Compound) resembles Valrubicin (Compound)
Idarubicin (Compound) treats breast cancer (Disease)
Idarubicin (Compound) binds CYP2C9 (Gene)
Idarubicin (Compound) upregulates MEGF8 (Gene)
Idarubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Idarubicin (Compound) downregulates CBR3 (Gene)
Idarubicin (Compound) causes Haemorrhage (Side Effect)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole